small molecule

FOTIVDA

TIVOZANIB HYDROCHLORIDE

Loss of exclusivityNovember 2039latest FDA-listed patent expiry

CompanyAVEO Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand name	FOTIVDA
Active ingredient	TIVOZANIB HYDROCHLORIDE
Strength	EQ 0.89MG BASE
Dosage form	CAPSULE
Route	ORAL
Modality	Small molecule
FDA approval	March 2021
Marketing status	RX

Listed patents

Patent	Expires	Type
11504365	November 2039	use U-3476
7166722	November 2028	substance, product

Regulatory exclusivity

Code	Expires
NCE	March 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from AVEO Pharmaceuticals